SAFC is investing $10 million to increase cGMP commercial-scale API manufacturing capacity at its SAFC Pharma, Arklow, Ireland facility, and to expand capacity to enhance manufacturing operations at its Buchs, Switzerland facilities. The company will invest $4.7 million at the Arklow facility and will increase production capacity and capability. The site will upgrade the pilot plant and add additional vessels to increase chemistry capacity for API products. Additional enhancements are expec...